Clinical Trials
tricision's
independently developed Survivin-Targeting Dendritic Cell (DC) Cell
Injection has reached a major milestone:
the Center for Drug Evaluation (CDE) has publicly listed the
product for formal initiation of a Phase II Clinical Trial (CT) (Registration
No. CTR20261465). CDE Phase II Filing Phase II Clinical Trial: First in China,
Benchmarking International Standards The Phase II CT is focused on newly
diagnosed GBM (World Health Organization (WHO) Grade IV) and will
comprehensively evaluate the vaccine's efficacy and safety. It is the first
Survivin-targeting agent to enter Phase II in China. Survivin is
internationally recognized as a core tumor antigen strongly correlated with
proliferation, recurrence, and drug resistance. Globally, only the SurVaxM
peptide vaccine (MimiVax, USA) targeting the same antigen has advanced to Phase
2b. tricision's mRNA-DC vaccine, with its distinct technological
approach, directly demonstrates China's growing capability in cellular
immunotherapy R&D. This achievement provides an accessible, safe, and effective treatment option for a disease that has long defied standard therapy. As the clinical program advances and the scope of application expands, it is poised to reshape the global GBM treatment paradigm, offering patients new hope for long-term survival and even clinical cure. Impressive Clinical Data: Long-Term
Survival and Safety Dual Breakthroughs Published clinical data show that the
therapy has achieved significant outcomes:
